Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been co...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. Avxentyev, I. I. Andreyashkina, E. V. Artamonova, L. V. Bolotina, E. I. Kovalenko, N. N. Sisigina
Format: Article
Language:Russian
Published: ABV-press 2024-05-01
Series:Опухоли женской репродуктивной системы
Subjects:
breast cancer
cyclin-dependent kinase 4 and 6 inhibitors
abemaciclib
palbociclib
ribociclib
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items